General information

Announcements(2)

Program

Sessions

Search presentations

Download PDF for print

Timetable

Mon. Mar 16, 2026

Tue. Mar 17, 2026

Wed. Mar 18, 2026

web_header.png

web_icon.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

Enter the password to view the abstracts.<br>The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Announcements

Profile management

Bookmark

Development of cancer-specific antibodies for clinical application using CasMab technology

While new modalities such as antibody-drug conjugates (ADCs) and chimeric antigen receptor T cells (CAR-T) are being developed in cancer antibody therapeutics, toxicity to normal tissues remains a persistent concern. To address this, we have developed CasMab technology for creating cancer-specific antibodies against membrane proteins, as well as the Cell-Based Immunization and Screening (CBIS) method, which enables the rapid generation of antibodies even against challenging targets. We are currently developing CasMabs for various membrane proteins through AMED projects and collaborative research with pharmaceutical companies. The key elements in generating CasMabs are target selection, antigen preparation, and screening methods, which do not necessarily require entirely new technologies. In this presentation, I will introduce our latest findings, focusing on the newly established HER2-CasMab.

The 99th Annual Meeting of the Japanese Pharmacological Society

Presentation Information

[2-SL-06]Development of cancer-specific antibodies for clinical application using CasMab technology

Keywords:

Password required to view

Comment